Haihan Song

Haihan Song


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2013 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
ZCZhanshan Cha
Zhanshan Cha
YZYan Zang
Yan Zang
HGHuijun Guo
Huijun Guo
JRJames R. Rechlic
James R. Rechlic
LOLindsay M. Olasnova
Lindsay M. Olasnova
BQBaohua Qian
Baohua Qian

23 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MCMing Cai
Ming Cai
JWJian Wan
Jian Wan
KCKeren Cai
Keren Cai
HSHaihan Song
Haihan Song
YWYujiao Wang
Yujiao Wang
JHJingyun Hu
Jingyun Hu
Lactate mediates multiple cell-intrinsic effects in cancer metabolism in terms of development, maintenance, and metastasis and is often correlated with poor prognosis. Its functions are undertaken as an energy source for neighboring carcinoma cells and serve as a lactormone for oncogenic signaling pathways. Indeed, two isomers of lactate are produced in the Warburg effect: L-lactate and D-lactate. L-lactate is the main end-production of glycolytic fermentation which catalyzes glucose, and tiny D-lactate is fabricated through the glyoxalase system. Their production inevitably affects cancer development and therapy. Here, we systematically review the mechanisms of lactate isomers production, and highlight emerging evidence of the carcinogenic biological effects of lactate and its isomers in cancer. Accordingly, therapy that targets lactate and its metabolism is a promising approach for anticancer treatment.

3 August 2023 in Microbial Pathogenesis
Verified
Journal Article
Closed access
JYJuan Yang
Juan Yang
LWLingling Wang
Lingling Wang
HLHuiqin Liu
Huiqin Liu
HXHui Xu
Hui Xu
FLFeng Liu
Feng Liu
HLHongqiang Li
Hongqiang Li

31 January 2022 in Biomaterials Research
Verified
Journal Article
Open access
PDF file
TLTongyu Li
Tongyu Li
WSWeiwei Shi
Weiwei Shi
JYJie Yao
Jie Yao
JHJingyun Hu
Jingyun Hu
QSQiong Sun
Qiong Sun
WHWang Hangxiang
Wang Hangxiang
Background: Combinatorial systemic chemotherapy is a powerful treatment paradigm against cancer, but it is fraught with problems due to the emergence of chemoresistance and additive systemic toxicity. In addition, coadministration of individual drugs suffers from uncontrollable pharmacokinetics and biodistribution, resulting in suboptimal combination synergy. Methods: Toward the goal of addressing these unmet medical issues, we describe a unique strategy to integrate multiple structurally disparate drugs into a self-assembling nanococktail platform. Conjugation of a polyunsaturated fatty acid (e.g., linoleic acid) with two chemotherapies generated prodrug entities that were miscible with tunable drug ratios for aqueous self-assembly. In vitro and in vivo assays were performed to investigate the mechanism of combinatorial nanococktails in mitigating chemoresistance and the efficacy of nanotherapy. Results: The coassembled nanoparticle cocktails were feasibly fabricated and further refined with an amphiphilic matrix to form a systemically injectable and PEGylated nanomedicine with minimal excipients. The drug ratio incorporated into the nanococktails was optimized and carefully examined in lung cancer cells to maximize therapeutic synergy. Mechanistically, subjugated resistance by nanococktail therapy was achieved through the altered cellular uptake pathway and compromised DNA repair via the ATM/Chk2/p53 cascade. In mice harboring cisplatin-resistant lung tumor xenografts, administration of the nanococktail outperformed free drug combinations in terms of antitumor efficacy and drug tolerability. Conclusion: Overall, our study provides a facile and cost-effective approach for the generation of cytotoxic nanoparticles to synergistically treat chemoresistant cancers.

2 March 2023 in Drug Delivery
Verified
Journal Article
Open access
SXShiyun Xian
Shiyun Xian
JZJiabin Zhu
Jiabin Zhu
YWYuchen Wang
Yuchen Wang
HSHaihan Song
Haihan Song
WHWang Hangxiang
Wang Hangxiang
Inflammatory bowel disease (IBD) is one of the most common intestinal disorders, with increasing global incidence and prevalence. Numerous therapeutic drugs are available but require intravenous administration and are associated with high toxicity and insufficient patient compliance. Here, an oral liposome that entraps the activatable corticosteroid anti-inflammatory budesonide was developed for efficacious and safe IBD therapy. The prodrug was produced via the ligation of budesonide with linoleic acid linked by a hydrolytic ester bond, which was further constrained into lipid constituents to form colloidal stable nanoliposomes (termed budsomes). Chemical modification with linoleic acid augmented the compatibility and miscibility of the resulting prodrug in lipid bilayers to provide protection from the harsh environment of the gastrointestinal tract, while liposomal nanoformulation enables preferential accumulation to inflamed vasculature. Hence, when delivered orally, budsomes exhibited high stability with low drug release in the stomach in the presence of ultra-acidic pH but released active budesonide after accumulation in inflamed intestinal tissues. Notably, oral administration of budsomes demonstrated favorable anti-colitis effect with only ∼7% mouse body weight loss, whereas at least ∼16% weight loss was observed in other treatment groups. Overall, budsomes exhibited higher therapeutic efficiency than free budesonide treatment and potently induced remission of acute colitis without any adverse side effects. These data suggest a new and reliable approach for improving the efficacy of budesonide. Our in vivo preclinical data demonstrate the safety and increased efficacy of the budsome platform for IBD treatment, further supporting clinical evaluation of this orally efficacious budesonide therapeutic.

1 January 2021 in Theranostics
Verified
Journal Article
Open access
XCXiaona Chen
Xiaona Chen
BXBinbin Xie
Binbin Xie
LHLingling Huang
Lingling Huang
JWJianqin Wan
Jianqin Wan
YWYuchen Wang
Yuchen Wang
WHWang Hangxiang
Wang Hangxiang
New strategies to fabricate nanomedicines with high translational capacity are urgently desired. Herein, a new class of self-assembled drug cocktails that addresses the multiple challenges of manufacturing clinically useful cancer nanomedicines was reported.